Immunity Immunization White Paper 
Pharmaceutical Technology
MARCH 20, 2023
The collaboration, under a sponsored research agreement, will focus on mRNA vaccines that can help in modulating the normal immune response of the body for the treatment of certain autoimmune diseases as well as allergic conditions. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Technology
DECEMBER 8, 2022
Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 17, 2023
CAR-T therapies are based on the patient’s immune cell modification and can express artificial chimeric receptors that can identify and remove tumour cells. This therapy is expected to be an improvement over CAR-T in relapsed patients, especially those who have less number of normal T lymphocytes.
Pharmaceutical Technology
JANUARY 10, 2023
The collaboration will combine 3T Biosciences’ 3T- T-Cell Receptor Antigen and Cross-Reactivity Engine (TRACE) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining compounds that are directed towards cancer cells and target immune cells.
FDA Law Blog: Biosimilars
APRIL 8, 2024
It also noted that last year, FDA hosted a two-day public workshop and published a white paper on the regulatory framework for Artificial Intelligence in drug manufacturing, in addition to other efforts. Like many of us, OPQ seems intent on trying to keep up with how technology can/will impact pharmaceutical quality.
Pharmaceutical Technology
JANUARY 27, 2023
It takes own immune cells of a patient and modifies them to attach and destroy cancer cells. The new CAR-T therapy will be given as a one-off intravenous infusion. Previously, it was available through the Cancer Drugs Fund (CDF).
Pharmaceutical Technology
FEBRUARY 28, 2023
It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials.
Expert insights. Personalized for you.
98 
Let's personalize your content